CABA · Insider Trading
Cabaletta Bio, Inc. Common Stock
Every open-market purchase and sale reported by CABA officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-06-10 | Shawn Tomasello | Director | A | +22,000 deriv. | — |
| 2026-06-10 | Catherine Bollard | Director | A | +22,000 deriv. | — |
| 2026-06-10 | Mark Simon | Director | A | +22,000 deriv. | — |
| 2026-06-10 | Richard C Henriques Jr | Director | A | +22,000 deriv. | — |
| 2026-06-10 | Scott C. Brun | Director | A | +22,000 deriv. | — |
| 2026-03-02 | Michael Gerard | General Counsel | A | +175,000 deriv. | — |
| 2026-03-02 | Arun Das | Chief Business Officer | A | +175,000 deriv. | — |
| 2026-03-02 | Steven Nichtberger | President & CEO | A | +674,000 deriv. | — |
| 2026-03-02 | Anup Marda | Chief Financial Officer | A | +225,000 deriv. | — |
| 2026-03-02 | David J. Chang | Chief Medical Officer | A | +225,000 deriv. | — |
| 2026-03-02 | Gwendolyn Binder | President, Science & Tech. | A | +225,000 deriv. | — |
| 2026-01-21 | Steve Gavel | Chief Commercial Officer | Buy | +22,170 | +$50.22K |
| 2026-01-21 | Shawn Tomasello | Director | Buy | +22,725 | +$50.32K |
| 2026-01-21 | Catherine Bollard | Director | Buy | +4,405 | +$9.98K |
| 2026-01-21 | Michael Gerard | General Counsel | Buy | +6,600 | +$14.98K |
| 2026-01-21 | Mark Simon | Director | Buy | +11,061 | +$25.26K |
| 2026-01-21 | Gwendolyn Binder | President, Science & Tech. | Buy | +11,312 | +$24.76K |
| 2026-01-21 | David J. Chang | Chief Medical Officer | Buy | +8,800 | +$19.89K |
| 2026-01-21 | Steven Nichtberger | President & CEO | Buy | +45,000 | +$100.78K |
| 2025-10-15 | Steve Gavel | CHIEF COMMERCIAL OFFICER | A | +275,000 deriv. | — |
| 2025-06-09 | Scott C. Brun | Director | A | +22,000 deriv. | — |
| 2025-06-09 | Catherine Bollard | Director | A | +22,000 deriv. | — |
| 2025-06-09 | Richard C Henriques Jr | Director | A | +22,000 deriv. | — |
| 2025-06-09 | Shawn Tomasello | Director | A | +22,000 deriv. | — |
| 2025-06-09 | Mark Simon | Director | A | +22,000 deriv. | — |
| 2025-05-19 | Richard C Henriques Jr | Director | MIXED | — | — |
| 2025-05-19 | Catherine Bollard | Director | MIXED | — | — |
| 2025-05-19 | Scott C. Brun | Director | MIXED | — | — |
| 2025-05-19 | Shawn Tomasello | Director | MIXED | — | — |
| 2025-05-19 | Gwendolyn Binder | President, Science & Tech. | MIXED | — | — |
| 2025-05-19 | Arun Das | Chief Business Officer | MIXED | — | — |
| 2025-05-19 | Anup Marda | Chief Financial Officer | MIXED | — | — |
| 2025-05-19 | Michael Gerard | General Counsel | MIXED | — | — |
| 2025-05-19 | Steven Nichtberger | President & CEO | MIXED | — | — |
| 2025-05-19 | Mark Simon | Director | MIXED | — | — |
| 2025-05-19 | David J. Chang | Chief Medical Officer | MIXED | — | — |
| 2025-03-04 | Anup Marda | Chief Financial Officer | A | +145,000 deriv. | — |
| 2025-03-04 | Gwendolyn Binder | President, Science & Tech. | A | +145,000 deriv. | — |
| 2025-03-04 | Steven Nichtberger | President & CEO | A | +450,000 deriv. | — |
| 2025-03-04 | Arun Das | Chief Business Officer | A | +115,000 deriv. | — |
| 2025-03-04 | David J. Chang | Chief Medical Officer | A | +145,000 deriv. | — |
| 2025-03-04 | Michael Gerard | General Counsel | A | +115,000 deriv. | — |
| 2024-06-04 | Shawn Tomasello | Director | A | +22,000 deriv. | — |
| 2024-06-04 | Scott C. Brun | Director | A | +22,000 deriv. | — |
| 2024-06-04 | Richard C Henriques Jr | Director | A | +22,000 deriv. | — |
| 2024-06-04 | Mark Simon | Director | A | +22,000 deriv. | — |
| 2024-06-04 | Catherine Bollard | Director | A | +22,000 deriv. | — |
| 2024-03-04 | Steven Nichtberger | President & CEO | A | +353,000 deriv. | — |
| 2024-03-04 | Anup Marda | Chief Financial Officer | A | +130,000 deriv. | — |
| 2024-03-04 | David J. Chang | Chief Medical Officer | A | +130,000 deriv. | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| Steven Nichtberger | President & CEO | 1,394,483 | $1.88M |
| Mark Simon | Director | 154,205 | $208.18K |
| Anup Marda | Chief Financial Officer | 50,000 | $67.50K |
| Gwendolyn Binder | President, Science & Tech. | 31,312 | $42.27K |
| Shawn Tomasello | Director | 22,725 | $30.68K |
| Steve Gavel | Chief Commercial Officer | 22,170 | $29.93K |
| David J. Chang | Chief Medical Officer | 8,800 | $11.88K |
| Michael Gerard | General Counsel | 6,600 | $8.91K |
| Catherine Bollard | Director | 5,405 | $7.30K |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the CABA quote page; the site-wide leaderboard is on the insider transactions hub.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.